Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 791-798

  Kobunai, Takashi ^a   Ooyama, Akio ^b   Sasaki, Shin ^a   Wierzba, Konstanty ^b   Takechi, Teiji ^b   Fukushima, Masakazu ^b   Watanabe, Toshiaki ^c   Nagawa, Hirokazu ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer; Chemotherapy; DNA copy number

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL; MESSENGER RNA; TEGAFUR; UFT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DATA BASE; DRUG SENSITIVITY; GENE EXPRESSION; HEALTH CARE ORGANIZATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; MICROARRAY ANALYSIS; NEOPLASMS; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 33947715687     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.09.026     Document Type: Article

References (25)

1. van Triest B., van Groeningen C.J., and Pinedo H.M. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer A 31 (1995) 1193-1197
2. Callagy G., Pharoah P., Chin S.F., et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 205 (2005) 388-396
3. Weiss M.M., Kuipers E.J., Postma C., et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 26 (2004) 307-317
4. Rubio-Moscardo F., Climent J., Siebert R., et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105 (2005) 4445-4454
5. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
6. van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist 10 Suppl. 2 (2005) 30-34
7. Barrier A., Boelle P.Y., Lemoine A., et al. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 48 (2005) 2238-2248
8. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
9. Roschke A.V., Tonon G., Gehlhaus K.S., et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63 (2003) 8634-8647
10. Ooyama A., Takechi T., Toda E., et al. Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci 97 (2006) 510-522
11. Zhao X., Li C., Paez J.G., et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 64 (2004) 3060-3071
12. Yoshinare K., Kubota T., Watanabe M., et al. Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94 (2003) 633-638
13. Takechi T., Fujioka A., Matsushima E., and Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38 (2002) 1271-1277
14. Kidd E.A., Yu J., Li X., et al. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 11 (2005) 2612-2619
15. Smorenburg C.H., Peters G.J., van Groeningen C.J., et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropryimidine dehydrogenase. Ann Oncol 17 (2006) 35-42
16. Grem J.L., Danenberg K.D., Behan K., et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 7 (2001) 999-1009
17. Etienne M.C., Cheradame S., Fischel J.L., et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13 (1995) 1663-1670
18. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
19. Ota D., Kusama M., Kaise H., et al. Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer. Breast Cancer 11 (2004) 356-366
20. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
21. Bohl C.E., Gao W., Miller D.D., et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102 (2005) 6201-6206
22. Hamilton M, Wolf JL, Zborowski D. Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib. AACR Annual Meeting, Anaheim, Orange County, CA, USA; 2005.
23. Johnston P.G., Lenz H.J., Leichman C.G., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55 (1995) 1407-1412
24. de Bruin M., van Capel T., Van der Born K., et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 88 (2003) 957-964
25. Bussey K.J., Chin K., Lababidi S., et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5 (2006) 853-867